Issue navigation
Volume 35, Issue Supplement_1, January 2020
The role of SGLT2 inhibitors in the management of chronic kidney disease
EDITORIAL
Editorial: The role of sodium-glucose cotransporter 2 inhibitors in the management of chronic kidney disease
Nephrology Dialysis Transplantation, Volume 35, Issue Supplement_1, January 2020, Pages i1–i2, https://doi.org/10.1093/ndt/gfz282
REVIEWS
Renal physiology of glucose handling and therapeutic implications
Nephrology Dialysis Transplantation, Volume 35, Issue Supplement_1, January 2020, Pages i3–i12, https://doi.org/10.1093/ndt/gfz230
Sodium-glucose cotransporter 2 inhibition: towards an indication to treat diabetic kidney disease
Nephrology Dialysis Transplantation, Volume 35, Issue Supplement_1, January 2020, Pages i13–i23, https://doi.org/10.1093/ndt/gfz237
Role of sodium-glucose cotransporter 2 inhibition to mitigate diabetic kidney disease risk in type 1 diabetes
Nephrology Dialysis Transplantation, Volume 35, Issue Supplement_1, January 2020, Pages i24–i32, https://doi.org/10.1093/ndt/gfz228
Sodium-glucose cotransporter 2 inhibitors: extending the indication to non-diabetic kidney disease?
Nephrology Dialysis Transplantation, Volume 35, Issue Supplement_1, January 2020, Pages i33–i42, https://doi.org/10.1093/ndt/gfz264
Sodium-glucose cotransporter 2 inhibitor effects on cardiovascular outcomes in chronic kidney disease
Nephrology Dialysis Transplantation, Volume 35, Issue Supplement_1, January 2020, Pages i43–i47, https://doi.org/10.1093/ndt/gfz292
Sodium-glucose cotransporter 2 inhibition: which patient with chronic kidney disease should be treated in the future?
Nephrology Dialysis Transplantation, Volume 35, Issue Supplement_1, January 2020, Pages i48–i55, https://doi.org/10.1093/ndt/gfz252
